S-8 1 uthr2023forms-8.htm S-8 Document

As filed with the Securities and Exchange Commission on August 2, 2023
Registration No. 333-    
     
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________

FORM S-8

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

United Therapeutics Corporation
(Exact Name of Registrant as Specified in the Charter)

Delaware52-1984749
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

1000 Spring Street
Silver Spring, MD

20910
(Address of principal executive offices)(Zip Code)

UNITED THERAPEUTICS CORPORATION
AMENDED AND RESTATED
2015 STOCK INCENTIVE PLAN
(Full title of the plan)

Paul A. Mahon, Executive Vice President and General Counsel
United Therapeutics Corporation
1000 Spring Street
Silver Spring, MD 20910
(301) 608-9292
(Name, address and telephone number, including area code, of agent for service)

Copy to:

Stephen I. Glover, Esq.
Gibson, Dunn & Crutcher LLP
1050 Connecticut Avenue, N.W.
Washington, D.C. 20036
(202) 955-8500
John S. Hess, Jr., Esq.
Executive Vice President and Deputy General Counsel
United Therapeutics Corporation
1735 Connecticut Avenue, N.W.
Washington, D.C. 20009
(202) 483-7000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


INTRODUCTION

This Registration Statement on Form S-8 is being filed by United Therapeutics Corporation, a Delaware public benefit corporation (the “Company” or the “Registrant”), in accordance with General Instruction E to Form S-8 relating to 1,000,000 shares of Common Stock, issuable to eligible individuals under the Plan, which 1,000,000 shares are in addition to (a) 6,150,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-205309) filed with the Securities and Exchange Commission on June 29, 2015, (b) 2,900,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-225942) filed with the Securities and Exchange Commission on June 28, 2018, (c) 450,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-232906) filed with the Securities and Exchange Commission on July 31, 2019, (d) 500,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-240156) filed with the Securities and Exchange Commission on July 29, 2020, (e) 1,000,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-258434) filed with the Securities and Exchange Commission on August 4, 2021, and (f) 500,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-266478) filed with the Securities and Exchange Commission on August 3, 2022, in each case together with all exhibits filed therewith or incorporated therein by reference ((a),(b), (c), (d), (e), and (f) collectively, the “Prior Registration Statements”). Except as supplemented by the information set forth herein, the contents of the Prior Registration Statements are incorporated herein by reference.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8.        Exhibits



* Filed herewith

[SIGNATURES ON THE NEXT PAGE]

1

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Silver Spring, State of Maryland, on this 2nd day of August, 2023.

UNITED THERAPEUTICS CORPORATION
By:
/s/ Martine A. Rothblatt
Martine A. Rothblatt, Ph.D.
Chairperson and Chief Executive Officer
        
POWER OF ATTORNEY


KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Martine A. Rothblatt, Ph.D., James C. Edgemond and Paul A. Mahon, and each of them, with full power of substitution and full power to act without the others, his or her true and lawful attorney-in-fact and agent, to act for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8, any and all amendments (including post-effective amendments) to this Registration Statement and any subsequent registration statement the Company may hereafter file with the Commission pursuant to Rule 462(b) under the Securities Act to register additional awards, and to file this Registration Statement and any subsequent registration statement and all amendments thereto, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto such attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do, and hereby ratifies and confirms all his said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in any number of counterparts, each of which shall constitute an original and all of which, taken together, shall constitute one Power of Attorney.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.

Name   Title   Date
     
/s/ Martine A. Rothblatt Chairperson and Chief Executive Officer
(Principal Executive Officer)		 August 2, 2023
Martine A. Rothblatt, Ph.D.
/s/ James C. Edgemond Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)		 August 2, 2023
James C. Edgemond
/s/ Christopher Causey Director August 2, 2023
Christopher Causey
/s/ Raymond Dwek Director August 2, 2023
Raymond Dwek
2

/s/ Richard Giltner Director August 2, 2023
Richard Giltner
/s/ Katherine Klein Director August 2, 2023
Katherine Klein
/s/ Ray Kurzweil Director August 2, 2023
Ray Kurzweil
/s/ Linda MaxwellDirectorAugust 2, 2023
Linda Maxwell
/s/ Nilda MesaDirectorAugust 2, 2023
Nilda Mesa
/s/ Judy OlianDirectorAugust 2, 2023
Judy Olian
/s/ Christopher PatuskyDirectorAugust 2, 2023
Christopher Patusky
/s/ Louis SullivanDirectorAugust 2, 2023
Louis Sullivan
/s/ Tommy ThompsonDirectorAugust 2, 2023
Tommy Thompson


3